CHICAGO--(

--(

BUSINESS WIRE

商业热线

)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease..

)--Tempus AI，Inc.（纳斯达克股票代码：TEM）是一家领先采用人工智能推进精准医学和患者护理的技术公司，今天宣布已完成收购Ambry Genetics，Ambry Genetics是一家公认的基因检测领导者，旨在通过了解遗传与疾病之间的关系来改善健康。。

“This acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies,” said Eric Lefkofsky, Founder and CEO of Tempus. “We are excited to welcome Ambry to the Tempus team as we work together to improve patient outcomes and transform treatment journeys through the power of technology.”.

Tempus创始人兼首席执行官埃里克·莱夫科夫斯基（EricLefkofsky）表示：“此次收购补充了我们利用诊断和数据推动创新的战略，进一步增强了我们向临床医生、患者和生命科学公司提供尖端解决方案的能力。”。“我们很高兴欢迎Ambry加入Tempus团队，因为我们共同努力，通过技术的力量改善患者的预后并改变治疗过程。”。

As previously disclosed in Tempus’ third quarter 2024 results, the company paid $375 million in cash and $225 million in shares at closing, of which $100 million is subject to a lock-up agreement until one year post-transaction close. Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team..

正如之前在Tempus 2024年第三季度业绩中披露的那样，该公司在交割时支付了3.75亿美元的现金和2.25亿美元的股票，其中1亿美元需要签订锁定协议，直至交易结束后一年。资金由Ares管理信贷基金提供。Ambry Genetics将继续作为Tempus的全资子公司在其当前的领导团队下运营。。

About Tempus

关于Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Tempus是一家通过人工智能在医疗保健中的实际应用来推进精准医学的技术公司。Tempus拥有世界上最大的多模式数据库之一，以及一个可访问和有用的操作系统，为医生提供人工智能支持的精准医学解决方案，以提供个性化的患者护理，同时促进最佳疗法的发现、开发和交付。

The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit .

目标是通过为医生提供工具，让每位患者在公司收集更多数据时学习，从而从之前的其他患者的治疗中受益。有关更多信息，请访问。

tempus.com

网站 tempus.com

.

.

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties.

本新闻稿包含经修订的《1933年证券法》（“证券法”）第27A节和经修订的《1934年证券交易法》第21E节所指的有关Tempus和Tempus行业的前瞻性声明，涉及重大风险和不确定性。

All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ acquisition of Ambry Genetics. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions.

除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括但不限于有关Tempus收购Ambry Genetics的声明。。

Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release..

Tempus提醒您，上述内容可能不包括本新闻稿中的所有前瞻性声明。。

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects.

。Tempus在本新闻稿中所载的前瞻性声明主要基于其对未来事件和趋势的当前预期和预测，它认为这些事件和趋势可能会影响Tempus的业务、财务状况、经营成果和前景。

These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future.

这些前瞻性声明存在以下风险和不确定性：Tempus产品和服务的预期用途；Tempus的财务表现；吸引和留住客户和合作伙伴的能力；管理Tempus的增长和未来支出；竞争和新市场进入者；遵守新的法律、法规和执行行动，包括人工智能领域任何不断发展的法规；维护、保护和增强Tempus知识产权的能力；吸引和留住合格团队成员和关键人员的能力；偿还或再融资未偿债务或获得额外融资的能力；未来收购、资产剥离或投资；包括我们实现收购Ambry Genetics的预期收益的能力；气候变化、自然灾害、健康流行病、宏观经济状况、战争或其他武装冲突的潜在不利影响，以及Tempus向美国证券交易委员会（“SEC”）提交的截至2024年9月30日季度的10-Q表季度报告中题为“风险因素”的部分中描述的风险、不确定性和其他因素，以及Tempus未来可能向SEC提交的其他文件中描述的因素。

In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertake.

此外，本新闻稿中包含的任何前瞻性声明均基于Tempus认为截至目前合理的假设。Tempus承担。